Latest guidance given with Q3 FY2026 results, 4 Nov 2026
| Measure | Period | Guidance | As stated |
|---|---|---|---|
| EPS · Adjusted | FY2026 | $8.50 to $8.60 | Adjusted Diluted EPS $8.50- $8.60 |
Source: the company's earnings release.
In its results release of 4 Nov 2026 (Q3 FY2026), Zimmer Biomet gave 1 forecast in figures, among them EPS (adjusted) of $8.50 to $8.60 for FY2026.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
| Measure | Period | Guidance | As stated |
|---|---|---|---|
| EPS · Adjusted | FY2026 | $8.50 to $8.60 | Adjusted Diluted EPS $8.50- $8.60 |
Source: the company's earnings release.
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|---|---|---|---|---|
| EPS · Adjusted | FY2026 | $8.50 to $8.60 | Raised 3 times | — | To come |
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.